Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Reported Saturday, Ocular Therapeutix™ Announced Phase 2 PAXTRAVA™ Glaucoma Data At ASCRS 2024 Annual Meeting

Author: Benzinga Newsdesk | April 08, 2024 03:27am

Phase 2 data highlight consistent and sustained reductions in Intraocular Pressure (IOP), statistically significant (p<0.0001) through six months, with clinically meaningful reductions of 24-30% achieved with a single PAXTRAVA implant
Generally well tolerated with no impact on corneal health observed
Consistent durability of IOP reduction and implant bioresorption shows potential for repeat dosing without stacking of implants
Expanded Focus on Retinal Disease Highlighted at the April 4th Eyecelerator

Posted In: OCUL